Patents by Inventor Mark C. Noe

Mark C. Noe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Isothiazole derivatives useful as anticancer agents
    Patent number: 7790902
    Abstract: The present invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein X1, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and to methods treating hyperproliferative disorders in mammals by administering the above compounds.
    Type: Grant
    Filed: July 29, 2008
    Date of Patent: September 7, 2010
    Assignees: Pfizer, Inc., OSI Pharmaceuticals, Inc.
    Inventors: Eric R. Larson, Mark C. Noe, Thomas G. Gant
  • Macrolides
    Patent number: 7462600
    Abstract: Macrolide compounds per se, as shown below and defined herein, and their use, e.g., as antibacterial and antiprotozoal agents in animals, including humans: Also disclosed are methods of preparing the compounds, intermediates, and pharmaceutical compositions thereof, and methods of treating or preventing disease by administering the compounds to subjects in need. This abstract is only an excerpt and is not limiting of the invention.
    Type: Grant
    Filed: December 21, 2005
    Date of Patent: December 9, 2008
    Assignee: Pfizer Inc
    Inventors: Louis S. Chupak, Mark E. Flanagan, Takushi Kaneko, Thomas V. Magee, Mark C. Noe, Usa Reilly
  • Isothiazole Derivatives Useful as Anticancer Agents
    Publication number: 20080300249
    Abstract: The present invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein X1, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and to methods treating hyperproliferative disorders in mammals by administering the above compounds.
    Type: Application
    Filed: July 29, 2008
    Publication date: December 4, 2008
    Applicants: PFIZER, INC., OSI PHARMACEUTICALS, INC.
    Inventors: Eric R. Larson, Mark C. Noe, Thomas G. Gant
  • Isothiazole derivatives useful as anticancer agents
    Patent number: 7405218
    Abstract: The present invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein X1, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and to methods treating hyperproliferative disorders in mammals by administering the above compounds.
    Type: Grant
    Filed: February 3, 2003
    Date of Patent: July 29, 2008
    Assignees: Pfizer, Inc., OSI Pharmaceuticals, Inc.
    Inventors: Eric R. Larson, Mark C. Noe, Thomas G. Gant
  • Selective inhibition of aggrecanase in osteoarthritis treatment
    Patent number: 7030242
    Abstract: This invention relates to a method of treatment for osteoarthritis involving inhibitors of aggrecanase that demonstrate IC50s of less than 20 nM and demonstrate differential potency against matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinases (ADAMs or reprolysins).
    Type: Grant
    Filed: May 3, 2005
    Date of Patent: April 18, 2006
    Assignees: Pfizer Inc, Pfizer Products Inc.
    Inventors: Mark C. Noe, Michael A. Letavic, Louis S. Chupak, Kim F. McClure
  • N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
    Patent number: 6919332
    Abstract: The present invention relates to N-substituted-heteroaryloxy-aryloxy-2,4,6-trione metalloproteinase inhibitors of the formula wherein X, A, Y, B, G, and R1 are as defined in the specification, and to pharmaceutical compositions and methods of treating inflammation, cancer and other disorders.
    Type: Grant
    Filed: April 28, 2003
    Date of Patent: July 19, 2005
    Assignee: Pfizer Inc.
    Inventors: Mark C. Noe, Lilli Ann Wolf-Gouveia
  • Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
    Patent number: 6916807
    Abstract: The present invention relates to triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors of the formula wherein said ring X is a 5-7 membered heterocyclic ring, and wherein A, Y, B, G, and W are as defined in the specification; and to pharmaceutical compositions and methods of treating inflammation, cancer and other disorders.
    Type: Grant
    Filed: April 25, 2003
    Date of Patent: July 12, 2005
    Assignee: Pfizer Inc.
    Inventors: Kevin D. Freeman-Cook, Mark C. Noe
  • N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
    Patent number: 6900201
    Abstract: The present invention relates to N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors of the formula wherein ring X is a 5-7 membered heterocyclic ring, and wherein A, Y, B, and G are as defined in the specification; and to pharmaceutical compositions and methods of treating inflammation, cancer and other disorders.
    Type: Grant
    Filed: April 25, 2003
    Date of Patent: May 31, 2005
    Assignee: Pfizer Inc.
    Inventors: Mark C. Noe, Kevin Freeman-Cook
  • Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
    Patent number: 6841671
    Abstract: The present invention relates to 5-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors of the formula wherein said “A” is a 5-7 membered heterocyclic ring as defined in the specification and to pharmaceutical compositions and methods of treating inflammation, cancer and other disorders.
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: January 11, 2005
    Assignee: Pfizer Inc.
    Inventors: Mark C. Noe, Martin J. Wythes, Brian S. Bronk
  • Pyrimidine-2,4,6-trione metalloproteinase inhibitors
    Patent number: 6706723
    Abstract: The present invention relates to pyrimidine-2,4,6-trione metalloproteinase inhibitors of the formula wherein X, Y, A, B and R1 are as defined in the specification, and to pharmaceutical compositions and methods of treating inflammation, cancer and other disorders.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: March 16, 2004
    Assignee: Pfizer, Inc.
    Inventors: Mark C. Noe, Lawrence A. Reiter, Martin J. Wythes
  • N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
    Publication number: 20040010141
    Abstract: The present invention relates to N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors of the formula 1
    Type: Application
    Filed: April 25, 2003
    Publication date: January 15, 2004
    Applicant: Pfizer Inc.
    Inventors: Mark C. Noe, Kevin Freeman-Cook
  • N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
    Publication number: 20030232849
    Abstract: The present invention relates to N-substituted-heteroaryloxy-aryloxy-2,4,6-trione metalloproteinase inhibitors of the formula 1
    Type: Application
    Filed: April 28, 2003
    Publication date: December 18, 2003
    Applicant: Pfizer Inc.
    Inventors: Mark C. Noe, Lilli Ann Wolf-Gouveia
  • Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
    Publication number: 20030225056
    Abstract: The present invention relates to triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors of the formula 1
    Type: Application
    Filed: April 25, 2003
    Publication date: December 4, 2003
    Applicant: Pfizer Inc.
    Inventors: Kevin D. Freeman-Cook, Mark C. Noe
  • TACE INHIBITORS
    Publication number: 20030181441
    Abstract: A compound of the formula 1
    Type: Application
    Filed: August 12, 1999
    Publication date: September 25, 2003
    Inventors: KIM MCCLURE, MARK C. NOE, MICHAEL A. LETAVIC, LOUIS S. CHUPAK
  • Gem substituted hydroxamic acids
    Patent number: 6608104
    Abstract: A compound of the formula wherein R1-R13, X, Z and Q are as defined above, useful in the treatment of arthritis, cancer, and other diseases involving the dysregulated production/release of reprolysins such as Aggrecanase and other diseases characterized by matrix metalloproteinase activity. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID's), COX-2 inhibitors and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer.
    Type: Grant
    Filed: March 27, 2001
    Date of Patent: August 19, 2003
    Assignee: Pfizer Inc
    Inventor: Mark C. Noe
  • Isothiazole derivatives useful as anticancer agents
    Publication number: 20030149048
    Abstract: The present invention relates to compounds of the formula 1 1
    Type: Application
    Filed: February 3, 2003
    Publication date: August 7, 2003
    Applicant: Pfizer Inc.
    Inventors: Eric R. Larson, Mark C. Noe, Thomas G. Gant
  • Arylsulfonyl hydroxamic acid derivatives
    Patent number: 6599890
    Abstract: A compound of the formula wherein R1, R2 R3, R4 R5, R6, R7, R8, R9 and Q are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID'S) and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer.
    Type: Grant
    Filed: November 8, 2000
    Date of Patent: July 29, 2003
    Assignee: Pfizer Inc
    Inventors: Kim F. McClure, Mark C. Noe, Michael A. Letavic, Louis S. Chupak
  • Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
    Publication number: 20030096803
    Abstract: The present invention relates to 5-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors of the formula 1
    Type: Application
    Filed: October 23, 2001
    Publication date: May 22, 2003
    Inventors: Mark C. Noe, Martin J. Wythes, Brian S. Bronk
  • Isothiazole derivatives useful as anticancer agents
    Patent number: 6548526
    Abstract: The present invention relates to compounds of the formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein X1, R1, R2 and R3 are as defined herein. The invention also relates to pharmaceutical compositions containing the above compounds and to methods treating hyperproliferative disorders in mammals by administering the above compounds.
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: April 15, 2003
    Assignee: Pfizer Inc
    Inventors: Eric R. Larson, Mark C. Noe, Thomas G. Gant
  • Hydroxy pipecolate hydroxamic acid derivatives
    Publication number: 20030008901
    Abstract: A compound of the formula 1
    Type: Application
    Filed: December 3, 2001
    Publication date: January 9, 2003
    Inventors: Kim F. McClure, Mark C. Noe, Michael A.. Letavic, Louis S. Chupak